1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Research
2.2. Quantitative Research
2.3. Market Breakdown & Data Triangulation
2.3.1. Primary & Secondary Research End-use Vendors
2.3.2. Secondary Research
2.3.3. Primary Research
2.4. Breakdown of Primary Research Respondents, By Region
2.5. Assumption & Limitation
3. Executive Summary
4. Global Pneumonia Therapeutics Market Insights
4.1. Industry Value Chain Analysis
4.2. DROC Analysis
4.2.1. Growth Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porters Five Forces Analysis
4.3.1. Bargaining End-use Industry of Suppliers
4.3.2. Bargaining End-use Industry of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Intensity of Rivalry
4.4. Recent Development/ Technological Advancement
4.5. Regulatory Insights
5. Global Pneumonia Therapeutics Market Overview
5.1. Market Size & Forecast by Value, 2018-2028
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Therapeutics
5.2.1.1. Prevention Vaccine
5.2.1.2. Treatment Drugs
5.2.1.3. Oxygen Therapy
5.2.2. By Drug Class
5.2.2.1. Antibacterial Drugs
5.2.2.1.1. Macrolide
5.2.2.1.2. Quinolones
5.2.2.1.3. Others
5.2.2.2. Antiviral Drugs
5.2.2.3. Antifungal Drugs
5.2.3. By Age Group
5.2.3.1. Paediatric
5.2.3.2. Adult
5.2.3.3. Geriatric
5.2.4. By Infection Type
5.2.4.1. Hospital-acquired Pneumonia [HAP]
5.2.4.2. Community-acquired Pneumonia [CAP]
5.2.4.3. Ventilator-associated Pneumonia [VAP]
5.2.5. By Distribution Channel
5.2.5.1. Hospital Pharmacies
5.2.5.2. Retail Pharmacies
5.2.5.3. Online Pharmacies
5.2.6. By Region
5.2.3.1. North America
5.2.3.2. Europe
5.2.3.3. Asia-Pacific
5.2.3.4. Latin America
5.2.3.5. Middle East and Africa
6. North Pneumonia Therapeutics Market
6.1. Market Size & Forecast by Value, 2018-2028
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Therapeutics
6.2.2. By Drug Class
6.2.3. By Age Group
6.2.4. By Infection Type
6.2.5. By Distribution Channel
6.2.6. By Country
6.2.6.1. U.S.
6.2.6.2. Canada
7. Europe Pneumonia Therapeutics Market
7.1. Market Size & Forecast by Value, 2018-2028
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Therapeutics
7.2.2. By Drug Class
7.2.3. By Age Group
7.2.4. By Infection Type
7.2.5. By Distribution Channel
7.2.6. By Country
7.2.6.1. France
7.2.6.2. Germany
7.2.6.3. Italy
7.2.6.4. Spain
7.2.6.5. Rest of Europe
8. The Asia-Pacific (APAC) Pneumonia Therapeutics Market
8.1. Market Size & Forecast by Value, 2018-2028
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Therapeutics
8.2.2. By Drug Class
8.2.3. By Age Group
8.2.4. By Infection Type
8.2.5. By Distribution Channel
8.2.6. By Country
8.2.6.1. Japan
8.2.6.2. China
8.2.6.3. India
8.2.6.4. South Korea
8.2.6.5. Rest of APAC
9. Latin America Pneumonia Therapeutics Market
9.1. Market Size & Forecast by Value, 2018-2028
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Therapeutics
9.2.2. By Drug Class
9.2.3. By Age Group
9.2.4. By Infection Type
9.2.5. By Distribution Channel
9.2.6. By Country
9.2.6.1. Brazil
9.2.6.2. Argentina
9.2.6.3. Mexico
9.2.6.4. Rest of Latin America
10. The Middle East & Africa (MEA) Pneumonia Therapeutics Market
10.1. Market Size & Forecast by Value, 2018-2028
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1. By Therapeutics
10.2.2. By Drug Class
10.2.3. By Age Group
10.2.4. By Infection Type
10.2.5. By Distribution Channel
10.2.6. By Country
10.2.6.1. South Africa
10.2.6.2. Saudi Arabia
10.2.6.3. U.A.E.
10.2.6.4. Rest of MEA
11. Competitive Landscape
11.1. List of Key Players and their Offerings
11.2. Company Market Share Analysis, 2021
11.3. Competitive Benchmarking, By Operating Parameters
12. Impact of Covid-19 across Global Pneumonia Therapeutics Market
13. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
13.1. Merck & Co, Inc
13.2. Sanofi SA
13.3. AstraZeneca plc
13.4. Eli Lilly and Company
13.5. Teva Pharmaceutical Industries Ltd
13.6. Abbvie Inc
13.7. Novartis International AG
13.8. Abbott Laboratories
13.9. Bayer AG
13.10. Pfizer Inc
13.11. GlaxoSmithKline Plc
13.12. Lupin Pharmaceuticals, Inc
14. Key Strategic Recommendations
*Financial details of unlisted companies will be available as per data availability in the final deliverable
**The segmentation and the companies are subjected to modifications based on the in-depth secondary for the final deliverable